Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.
Training programme on exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.
Human R&D, Training
H2020-MSCA-ITN-2019 – Grant Agreement ID 953407
1 January 2021 to 31 December 2024
The “INTERCEPT-MDS” project aims to explore the fascinating concept of disease interception – a treatment of disease in its early stages by selectively removing altered cells – in myelodysplastic syndromes. To do this, the consortium sets out to overcome key challenges: 1) identification of few altered disease cells among many healthy ones and 2) development of therapies specifically targeting disease-driving cells. GenomeScan, as a partner in the consortium, will provide expertise in NGS, Bio-IT and single-cell sequencing.
T.b.a. (ongoing project)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 953407.